DR. LAL PATHLABS LIMITED

Analyst Reco. Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Delayed NSE India S.E. Other stock markets 05:32:50 2024-06-06 am EDT			5-day change	1st Jan Change
2,753 ^INR	-0.80%		+4.74%	+6.76%

May. 14	Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	MT
May. 10	Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	May. 14	MT
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	Feb. 05	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	Nov. 06	MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835	23-07-31	MT
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR1,835 From INR1,864, Keeps at Neutral	23-05-15	MT
Nomura Upgrades Dr. Lal PathLabs to Neutral From Reduce, Adjusts Price Target to INR1,864 From INR1,819	23-02-06	MT
CARE Assigns AA Rating on Dr. Lal Pathlabs' Long-term Bank Financing; Outlook Stable	23-01-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer